Drug intelligence / Profile preview

89Zr-DFO-STEAP1 antibody

Development stage
Preclinical
Lead developer
Genentech
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

89Zr-DFO-STEAP1 antibody is a radiolabeled monoclonal antibody being developed as an immuno-PET imaging agent and theranostic tool for prostate cancer. It consists of a humanized IgG1 monoclonal antibody targeting six-transmembrane epithelial antigen of the prostate 1 (STEAP1), conjugated to the chelator deferoxamine (DFO) and radiolabeled with the positron-emitting isotope zirconium-89 (89Zr). STEAP1 is highly expressed in prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC), making it an attractive target for patients with low or absent PSMA expression. Preclinical studies at the University of Wisconsin-Madison have demonstrated that the tracer exhibits high tumor uptake and retention with rapid clearance from normal tissues, supporting its potential as a companion diagnostic for STEAP1-targeted therapies.

Other names
89Zr-DFO-STEAP189Zr-DFO-STEAP1 antibody[89Zr]Zr-DFO-STEAP1[89Zr]Zr-DFO-STEAP1 antibody
02

Identity

Drug type
Antibody-Based Therapeutics
Originator
Memorial Sloan Kettering Cancer Center
Modality
Monoclonal AntibodiesAntibody-Radionuclide ConjugatesPositron EmittersGamma Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
prostate cancer and precursor lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Memorial Sloan Kettering Cancer CenterOriginator
  • GenentechLead developer
07

Competitive landscape

Drugs on the same target
13
Drugs in the lead indication
564

Lead indication: prostate cancer and precursor lesions

Most advanced in the lead indication

  1. 18F-PSMA-11Approved
  2. aminocaproic acidApproved
  3. bicalutamideApproved
  4. degarelixApproved
  5. flotufolastat f 18Approved

Beyond the preview

Go deeper on 89Zr-DFO-STEAP1 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-DFO-STEAP1 antibody.

Work on 89Zr-DFO-STEAP1 antibody? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call